What Macrocyclics does

Macrocyclics is a Plano, Texas-based contract development and manufacturing organization (CDMO) that designs, synthesizes, and supplies macrocyclic chelating agents used to bind radioactive metal ions for radiopharmaceuticals, MRI contrast agents, and nuclear medicine research applications. Founded in 1995 by Professor A. Dean Sherry as a successor to Magnetic Resonance Solutions (1993), the company operates from a 20,000-square-foot facility equipped with two modular cGMP manufacturing suites, kilo-scale production equipment, and labs licensed for radionuclides used in PET imaging and therapeutic applications. Its core technology is macrocyclic chelation chemistry, with proprietary expertise spanning bifunctional chelators (DOTA, DTPA, NOTA, DOTAGA derivatives), macrocyclic ligands, pre-formed lanthanide complexes (e.g., Lu-DOTA, Gd-DOTA), and the Macropa™ platform for Ac-225 targeted alpha therapy, which is held under exclusive sublicense from Ratio Therapeutics.

The company's revenue model combines a transactional e-commerce catalog of more than 100 chelating agents and related reagents with project-based custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services quoted directly to enterprise customers. Pricing on catalog items ranges from roughly $62 to over $8,500 per unit, while custom and GMP work is quoted on multi-week lead times (a 10-week minimum for GMP production, with quotations issued within two weeks). Primary customers are pharmaceutical and biotechnology developers of radiopharmaceuticals and nuclear medicine programs, with a secondary segment of academic and molecular imaging research institutions. Marketing is heavily concentrated in industry conferences (SNMMI, WMIC, TRP Summit, ACS) and scientific publications.

Macrocyclics operates as a wholly-owned subsidiary of Orano Med, itself part of French nuclear conglomerate Orano Group, following an October 2011 acquisition that originated from an earlier cGMP contract for Orano Med's Pb-212 clinical program. The relationship with Orano Med underpins capital expansion: the company doubled its footprint in 2019 (Phase II) and completed a further Phase III expansion in June 2025, concurrent with acquiring exclusive Macropa™ commercial rights. Leadership rests with a small, PhD-heavy operations team including CEO Paul Jurek, Senior Chemist Eric Anderson, Production Lead Federico Rojas, and Manager of Business Development Duke Halloran.

Name

Macrocyclics

Legal name

Macrocyclics, Inc.

Website

https://macrocyclics.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Macrocyclics is a Plano, Texas-based CDMO that designs and manufactures macrocyclic chelating agents and cGMP APIs for radiopharmaceutical and nuclear medicine developers worldwide. It serves pharma, biotech, and academic research customers through catalog sales, custom synthesis, bioconjugation, and clinical-stage GMP manufacturing.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

akta.pro secondary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Macrocyclic chelating agents
• Radiopharmaceutical manufacturing
• CGMP API production
• Bifunctional chelators
• MRI contrast chemistry

Headquarters

HQ city

Plano

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Catalog Product Sales: Sale of catalog chelating agents and related compounds through an e-commerce platform. Products include Bifunctional Chelators (BFCs), Macrocyclic Ligands, Magnetic Resonance Reagents, Reactive Intermediates, Fluorescent Probes, Conjugates, and Macropa for Ac-225. Pricing ranges from $62 to over $8,500 per unit depending on product and quantity.
2. cGMP Manufacturing for Clinical Trials: Custom GMP production of chelating agents, labeling precursors, and small molecule APIs for clinical investigation. Includes feasibility studies, engineering runs, GMP manufacturing, and final project reports with Statement of Work, raw materials data package, and Certificates of Analysis. 10-week minimum lead time; quoted upon request.
3. Custom Organic Synthesis: Custom synthesis of new linker mechanisms, drug conjugates, imaging precursors, and complex intermediates at scales from multi-milligram to multi-gram and kilogram. Services include modification to chelator/linker, small molecule conjugates, and PET tracer precursors.
4. Bioconjugation Services: Pre-clinical conjugation services for clinical trials, including evaluation of conjugation chemistries, proof-of-concept scale to multi-gram manufacturing, and stability protocols. Supports random lysine, interchain cysteine, and enzymatic/size click-chemistry conjugation mechanisms.
5. Analytical Testing Services: Standalone analytical services including HPLC qualification, HRMS-based Chelate Antibody Ratio analysis, impurity identification, and stability programs. Can be initiated as independent services or as part of cGMP development projects.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Macrocyclics designs, synthesizes, and manufactures macrocyclic chelating agents and cGMP-grade APIs that bind radioactive and lanthanide metal ions for radiopharmaceuticals, targeted alpha therapy, and MRI contrast agents. It sells a 100+ SKU catalog of bifunctional chelators, conjugates, macrocyclic ligands, MR reagents, reactive intermediates, fluorescent probes, and the Macropa™ Ac-225 platform, while providing integrated custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services for clinical-stage nuclear medicine programs.

Product overview

Macrocyclics is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. The product portfolio includes seven core product categories: Bifunctional Chelators (BFCs) with functionalized DOTA, DTPA, NOTA derivatives for targeting vector conjugation; Conjugates including DOTATATE and biotinylated compounds; Macrocyclic Ligands such as DOTA, NOTA, PCTA, and proprietary Macropa; Magnetic Resonance Reagents with pre-formed lanthanide complexes; Reactive Intermediates for custom synthesis; Fluorescent Probes for optical imaging; and the licensed Macropa™ platform for Ac-225 alpha therapy. The company also offers four service modules: cGMP manufacturing under ICH Q7/21 CFR 210&211, Custom Organic Synthesis, Bioconjugation, and Analytical Testing. Products are distributed from Plano, Texas with capabilities from multi-milligram research to kilogram-scale GMP production.

Differentiator

Problem solved

Functional benefit

Brands

• Macropa™: A proprietary chelator compound sublicensed by Macrocyclics for Ac-225 radiopharmaceutical applications.

Products and services

• Bifunctional Chelators (BFCs)

Quantifiable outcome

• 10-week minimum lead time for GMP production including manufacturing, drying, testing, and product release
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Ratio Therapeutics, Inc.coreOEM/ Whitelabel/ Licensing Partner · 13 June 2025Macrocyclics acquired exclusive manufacturing and distribution rights for the Macropa™ chelator platform from Ratio Therapeutics in June 2025. Under the sublicense, Macrocyclics holds exclusive rights to manufacture, market, and commercially distribute Macropa as a standalone CDMO. Field-of-use restrictions prohibit use in PSMA or SSTR2 diagnostic/therapeutic applications without separate authorization from Ratio. Volume limitations apply: only up to 10mg vials per purchase order unless the customer has a separate license with Ratio.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Curium Pharma: World's largest pure-play radiopharmaceutical manufacturer producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a downstream customer/partner for chelators, but operates at finished-drug scale rather than the CDMO chelator niche where Macrocyclics sits.
• Bachem: Swiss peptide CDMO with growing radioligand and oligonucleotide offerings. Comparable as a specialty CDMO supplying components to radiopharmaceutical developers, with GMP manufacturing scale well beyond Macrocyclics.
• GE HealthCare: Major supplier of PET radiopharmaceuticals, MRI contrast agents, and molecular imaging consumables. Comparable as a broad incumbent in the radiopharmaceutical and contrast-agent space where Macrocyclics supplies enabling chemistry.
• Thermo Fisher Scientific (Patheon / Cambrex): Largest global CDMO network offering small-molecule API manufacturing, peptide synthesis, and radiopharmaceutical services through its Patheon/Cambrex franchises. Competes with Macrocyclics on GMP API manufacturing and custom synthesis, but as part of a much broader portfolio.
• CordenPharma: Global CDMO with peptide and radioligand manufacturing capabilities serving radiopharmaceutical developers. Comparable as a CDMO serving radiopharma customers, but operates at significantly larger scale and broader modality scope than Macrocyclics.

Direct peers

• ABX Advanced Biochemical Compounds: German manufacturer of chelating agents (NOTA, DOTA, DTPA derivatives) and radiopharmaceutical precursors. Directly competes with Macrocyclics in supplying bifunctional chelators and custom radiolabeling precursors to pharma and academic researchers.
• IsoTherapeutics: US-based radiopharmaceutical CDMO providing custom radiosynthesis, cold kits, and contract manufacturing for nuclear medicine developers. Comparable as a specialized radiopharma CDMO serving pharma and academic customers, though Macrocyclics is more chelator-focused.
• Chematech: French specialty chemical manufacturer focused on polyazamacrocyclic ligands and chelating agents for nuclear medicine and radiopharmaceutical applications. Closely comparable to Macrocyclics in macrocyclic ligand chemistry and catalog offerings.

Regional players

• NTP Radioisotopes: South African state-linked producer and distributor of medical radioisotopes (Mo-99, I-131, Lu-177) and radiopharmaceuticals. Comparable as a vertically integrated radiopharma supplier, though primarily serving African and select international markets rather than the US CDMO niche Macrocyclics occupies.

Emerging players

• ITM (Isotope Technologies Munich): German radiopharmaceutical group focused on therapeutic and diagnostic radioisotopes (Lu-177, Ac-225) and radioligand therapies. Comparable as an emerging player in the targeted radionuclide therapy space where Macrocyclics' Macropa for Ac-225 is positioned to supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/macrocyclics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macrocyclics